Vor Biopharma Completes Enrollment in Phase 3 Trial of Investigational Drug for Generalized Myasthenia Gravis

07:46 AM EDT, 09/08/2026 (MT Newswires) -- Vor Biopharma (VOR) completed enrollment in Upstream MG, a global phase 3 registrational trial evaluating telitacicept in patients with generalized myasthenia gravis, a rare autoimmune disorder, the company said Tuesday. Topline results from the trial's 24-week primary endpoint remain expected in H1 2027, the company said. Vor Biopharma plans to launch Upstream oMG, a global phase 3 trial evaluating telitacicept in ocular myasthenia gravis, with first patient dosing expected in H1 2027. Vor Biopharma shares were down over 1% in premarket activity Tuesday.